

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As the below named inventor, I hereby declare that:

My residence, post office address and citizenship is as stated below next to my name;

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

POLYPEPTIDES CAPABLE OF INTERACTING WITH ONCOGENIC MUTANTS OF THE p53 PROTEIN

the specification of which:	is attached hereto.is attached hereto.is was filed on:as Application No.:and was amended on	i: (if applicable).
including the claims, as ame	ended by any amendment	s of the above-identified specification, referred to above. I acknowledge the tability as defined in 37 C.F.R. § 1.56.
And I hereby authori whose address is set forth I said application when know	below, to insert above, the	ts, Brobeck, Phleger & Harrison LLP, e filing date and application number of

Prior Foreign Application(s)

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application(s) for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Country	Application Number	Date of Filing (day, month, year)	Date of Issue (day, month, year)	Priority Claimed
France	98/12754	12 Oct. 1998		Yes No

Prior Provisional Application(s)

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application	Date of Filing	
Number	(day, month, year)	
60/132,331	3 May 1999	



Prior United States Application(s)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

	Application	Date of Filing	Status - Patented,	
	Number	(day, month, year)	Pending, Abandoned	
Р	CT/FR99/02465	12 October 1999	published	

And I hereby appoint, both jointly and severally, as my co-principal attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith the following attorneys, their registration numbers being listed after their names:

David J. Kulik, Registration No. 36,576 and James Remenick, Registration No. 36,902 of the firm

Brobeck, Phleger & Harrison LLP, Washington, D.C., Customer Number 26118;

and Rodger L. Tate, Registration No. 27,399; Anthony W. Shaw, Registration No. 30,104; Michael J. Songer, Reg. No. 39,841; Cono A. Carrano, Registration No. 39,623; Laurence H. Posorske, Registration No. 34,698; Floyd B. Chapman, Registration No. 40,555; Robert A. King, Registration No. 42,738; and Trevor Q. Coddington, Registration No. 46,633, all associated with Brobeck, Phleger & Harrison LLP.

And I hereby appoint, both jointly and severally, as my co-principal attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith, the following attorneys:

Ross J. Oehler, Registration No. 33,270, Aventis Pharmaceuticals Inc., Bridgewater, New Jersey, and Judy G. Barrett, Registration No. 37,086, Aventis Pharmaceuticals Inc., Hayward, California, each associated with **Customer Number 005487**.

All correspondence and telephone communications should be addressed to:

David J. Kulik, Esq. Brobeck, Phleger & Harrison LLP Intellectual Property Department 1333 H Street, N.W.; Suite 800 Washington, DC 20005

telephone number (202) 220-6000; facsimile number (202) 220-5200.



I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine and imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

	Signature			Date	
	Full Name of First Inventor:	CONSEILLER (Family Name)	Emmanuel (First Given Name)		(Second Given Name)
	Citizenship:	France			
That the thin are the set of the truth that the thete of the first officer.	Residence:	10, rue de Plelo, F-7501	5 Paris, France		
	Post Office Address:	same as above			
	Signature			Date	
	Full Name of Second Inventor:	DEBUSSCHE (Family Name)	Laurent (First Given Name)		(Second Given Name)
	Citizenship:	France			,
	Residence:	112, avenue Jean-Jaurès, F-91200 Athis-Mons, France			
	Post Office Address:	same as above			
	Signature			Date	
	Full Name of Third Inventor:	GALLAGHER (Family Name)	William (First Given Name)		(Second Given Name)
	Citizenship:	Ireland			•
	Residence:	21, boulevard Arago, F-7	75013 Paris, France		
	Post Office Address:	same as above			